A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

Inclusion Criteria: Part 1: * International Classification of Disease-10 (ICD-10) diagnosis codes for both uterine fibroids (UF) (D25.X) and heavy menstrual bleeding (HMB), defined as menorrhagia (N92.0, N92.4) or menometrorrhagia (N92.1) in the electronic health record (EHR) system. * Plans to initiate or has initiated Oriahnn treatment within 14 days of study enrollment. * Able to provide photographs of their scalp within 14 days of Oriahnn initiation, based on instruction provided. Part 2: \- Changes in thickness, fullness or pattern of hair that results in less hair than normal, or hair shedding that is increased from normal in the Hair Questionnaire. Exclusion Criteria: * Current or history of hair thinning, hair loss, or alopecia (defined as physician-diagnosed or patient-reported hair loss). * Have a contraindication to receive Oriahnn per Prescribing Information. * Any of the following occurrences within 180 days prior to Oriahnn prescription. * Prescription for Oriahnn, another gonadotropin releasing hormone (GnRH) antagonist \[including Myfembree (relugolix, estradiol/norethindrone acetate\]) or GnRH agonist. * Pregnancy/Childbirth. * New diagnosis of thyroid disease. * New diagnosis of inflammation or infection of the scalp (e.g., psoriasis, tinea capitis). * Have taken medications or undergone therapies that may cause alopecia, hair loss, or both. This includes but is not limited to chemotherapy, checkpoint inhibitors, epidermal growth factor anta…